L'intérêt à découvert pour Celldex Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Celldex Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Celldex Therapeutics (NASDAQ:CLDX) Stock, Rapport sur les intérêts à découvert

CELLDEX THERAPEUTICS INC

Celldex Therapeutics

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics Inc

UBS analyst Trung Huynh maintains Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and lowers the price target from $44 to $38.

News

Price Target

Analyst Ratings

CLDX

UBS Maintains Buy on Celldex Therapeutics, Lowers Price Target to $38

Goldman Sachs analyst Richard Law maintains Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Neutral and lowers the price target from $36 to $31.

Goldman Sachs Maintains Neutral on Celldex Therapeutics, Lowers Price Target to $31

Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Overweight and lowers the price target from $46 to $43.

Morgan Stanley Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $43

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and lowers the price target from $80 to $50.

HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Lowers Price Target to $50

Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.74) by 9.46 percent. This is a 44.64 percent decrease over losses of $(0.56) per share from the same period last year. The company reported quarterly sales of $695.00 thousand which missed the analyst consensus estimate of $1.05 million by 33.59 percent. This is a 345.51 percent increase over sales of $156.00 thousand the same period last year.

Earnings

Earnings Misses

Celldex Therapeutics Q1 EPS $(0.81) Misses $(0.74) Estimate, Sales $695.00K Miss $1.05M Estimate

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and maintains $80 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target

Biotech

Events

General

Celldex Presents Histology Data From Phase 2 Study Of Barzolvolimab In EoE

Across the recent three months, 7 analysts have shared their insights on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $59.57, with a high estimate of $80.00 and a low estimate of $36.00. Highlighting a 11.42% decrease, the current average has fallen from the previous average price target of $67.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1745845243_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Celldex Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Edward Nash &#x7C;Canaccord Genuity &#x7C;Announces &#x7C;Buy &#x7C; $64.00&#x7C;- &#x7C; 
&#x7C;Judah Frommer &#x7C;Morgan Stanley &#x7C;Announces &#x7C;Overweight &#x7C; $46.00&#x7C;- &#x7C; 
&#x7C;Richard Law &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $36.00&#x7C;$42.00 &#x7C; 
&#x7C;Joseph Pantginis &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $80.00&#x7C;$80.00 &#x7C; 
&#x7C;Joseph Pantginis &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $80.00&#x7C;$80.00 &#x7C; 
&#x7C;Trung Huynh &#x7C;UBS &#x7C;Announces &#x7C;Buy &#x7C; $44.00&#x7C;- &#x7C; 
&#x7C;Kristen Kluska &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Overweight &#x7C; $67.00&#x7C;$67.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celldex Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celldex Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Celldex Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Celldex Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CLDX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Celldex Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Celldex Therapeutics</h2>
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
<h3>Celldex Therapeutics's Economic Impact: An Analysis</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Celldex Therapeutics's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -71.56%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -4007.83%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Celldex Therapeutics's ROE excels beyond industry benchmarks, reaching -6.14%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Celldex Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.83%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Celldex Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Celldex Therapeutics's Future

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Canaccord Genuity analyst Edward Nash initiated coverage on Celldex Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy rating and announced a price target of $64. Celldex Therapeutics shares closed at $19.57 on Friday. <a href="https://www.benzinga.com/quote/CLDX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Michael Mueller initiated coverage on SmartStop Self Storage REIT, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMA#NYSE">SMA</a>) with an Overweight rating and announced a price target of $36. Smartstop Self Storage shares closed at $33.45 on Friday. <a href="https://www.benzinga.com/quote/SMA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Paul Kearney initiated coverage on Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with an Underweight rating and announced a price target of $4. Kohl&#8217;s shares closed at $7.06 on Friday. <a href="https://www.benzinga.com/quote/KSS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo initiated coverage on Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with an Equal-Weight rating and announced a price target of $62. Zillow shares closed at $65.19 on Friday. <a href="https://www.benzinga.com/quote/ZG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert initiated coverage on Co-Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) with a Buy rating and announced a price target of $10. Co-Diagnostics shares closed at $0.35 on Friday.  <a href="https://www.benzinga.com/quote/CODX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying KSS stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="591" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28080117/image-194-1024x591.png" alt="" class="wp-image-890712" style="width:606px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28080117/image-194-1024x591.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28080117/image-194-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28080117/image-194-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28080117/image-194.png 1157w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45035424/top-3-health-care-stocks-that-may-rocket-higher-in-april">Top 3 Health Care Stocks That May Rocket Higher In April</a> </li>
</ul>
Photo via Shutterstock

Initiation

Pre-Market Outlook

Markets

Trading Ideas

CODX

This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday

Canaccord Genuity analyst Edward Nash initiates coverage on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy rating and announces Price Target of $64.

Canaccord Genuity Initiates Coverage On Celldex Therapeutics with Buy Rating, Announces Price Target of $64

In the last three months, 7 analysts have published ratings on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $60.0, along with a high estimate of $80.00 and a low estimate of $36.00. A 10.71% drop is evident in the current average compared to the previous average price target of $67.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1742508047_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Celldex Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Law</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$44.00</td>
<td>-</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Celldex Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Celldex Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Celldex Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Celldex Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CLDX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Celldex Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Celldex Therapeutics</h2>
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
<h3>Financial Insights: Celldex Therapeutics</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Celldex Therapeutics faced challenges, resulting in a decline of approximately -71.56% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Celldex Therapeutics's net margin excels beyond industry benchmarks, reaching -4007.83%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Celldex Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -6.14%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Celldex Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.83%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Celldex Therapeutics's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

7 Analysts Have This To Say About Celldex Therapeutics

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>B. Riley Securities analyst Kalpit Patel initiated coverage on ArriVent BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) with a Buy rating and announced a price target of $37. ArriVent BioPharma shares closed at $19.60 on Wednesday. <a href="https://www.benzinga.com/quote/AVBP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Noah Poponak initiated coverage on Amentum Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTM#NYSE">AMTM</a>) with a Neutral rating and announced a price target of $21. Amentum Holdings shares closed at $19.03 on Wednesday. <a href="https://www.benzinga.com/quote/ANTM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Judah Frommer initiated coverage on Celldex Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with an Overweight rating and announced a price target of $46. Celldex Therapeutics shares closed at $19.95 on Wednesday. <a href="https://www.benzinga.com/quote/CLDX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Detlef Winckelmann initiated coverage on International Paper Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>) with an Overweight rating and announced a price target of $59. International Paper shares closed at $52.62 on Wednesday. <a href="https://www.benzinga.com/quote/IP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank analyst Patrick Colville initiated coverage on Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Sector Outperform rating and announced a price target of $470. Microsoft shares closed at $387.82 on Wednesday. &nbsp;<a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MSFT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="568" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20095446/image-182-1024x568.png" alt="" class="wp-image-833840" style="width:465px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20095446/image-182-1024x568.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20095446/image-182-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20095446/image-182-768x426.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20095446/image-182.png 1133w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44396642/jim-cramer-says-tjx-is-terrific-recommends-buying-these-stocks">Jim Cramer Says TJX Is &#8216;Terrific,&#8217; Recommends Buying These Stocks</a></li>
</ul>
Photo: Shutterstock

AMTM

AVBP

MSFT

This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Morgan Stanley analyst Judah Frommer initiates coverage on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Overweight rating and announces Price Target of $46.

Morgan Stanley Initiates Coverage On Celldex Therapeutics with Overweight Rating, Announces Price Target of $46

Goldman Sachs analyst Richard Law maintains Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Neutral and lowers the price target from $42 to $36.

Goldman Sachs Maintains Neutral on Celldex Therapeutics, Lowers Price Target to $36

- CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin - - Phase 1 study in healthy volunteers ongoing -
HAMPTON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) announced today positive preclinical data from CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis—thymic stromal lymphopoietin (TSLP) and mast cell depletion via stem cell factor (SCF) starvation.
The data demonstrate that CDX-622 neutralizes both SCF and TSLP, reducing tissue mast cells and inhibiting Type 2 inflammatory responses, supporting its potential to improve clinical activity over single target inhibition in inflammatory diseases and fibrotic disorders. The data were presented by Diego Alvarado, PhD, Vice President of Research at Celldex Therapeutics, in a poster presentation (<a href="https://www.globenewswire.com/Tracker?data=sN9mplLcyNg7kZz6whdneTYGR9NVNAbGu3mpTxlfnGAllPeA2wfq354iEjNNGsjJs_ixVls2nRks5tA19DkLaO7fNTwmpYzG9xHZ6kSDqmxWTAFslHPvpK-KbpDrbObU">#708</a>) as part of the American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting 2025.

Celldex Therapeutics Presents Preclinical Data From Inflammatory Bispecific Antibody Program CDX-622 At AAAAI 2025; CDX-622 Inhibits SCF And TSLP-Dependent Inflammatory Signatures In Human Skin

<ul>
<li>Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU.</li>
<li>82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52.</li>
<li>60% of CIndU patients reported that symptoms no longer had an impact on their quality of life at Week 12</li>
</ul>

Health Care

On Saturday, Celldex Therapeutics Announced Data On Measurements Of Disease Control And Quality Of Life From The Company's Phase 2 Barzolvolimab Studies In Patients With Chronic Urticaria

6 analysts have shared their evaluations of Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.67, with a high estimate of $80.00 and a low estimate of $44.00. This current average represents a 6.86% decrease from the previous average price target of $74.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1740744064_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Celldex Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$44.00</td>
<td>-</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celldex Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celldex Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Celldex Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Celldex Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CLDX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Celldex Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Celldex Therapeutics's Background</h2>
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
<h3>Celldex Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Celldex Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 110.35%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Celldex Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1319.99% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -5.27%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Celldex Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -5.05%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Celldex Therapeutics's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics

Guidance

Celldex Expects Cash And Equivalents Sufficient To Meet Estimated Working Capital Requirements And Fund Current Planned Operations Through 2027

Press Releases

Celldex Therapeutics to Present at Upcoming Investor Conferences

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

Comments

Celldex Therapeutics

Intérêt court

Celldex Therapeutics (NASDAQ:CLDX) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL